Look for:

Our offer for

ADDEX THERAPEUTICS LIMITED


ISIN:
CH0029850754
WKN:
2985075

2024/08/16 17:31:02
Price
0.052 CHF
Difference -10.34% (-0.01)

General attributes

ISINCH0029850754
SymbolADXN
ExchangeSIX Swiss Exchange
CurrencyCHF
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)5 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)0.052 CHF (32,183)
Ask (Ask size)0.0578 CHF (100)
Open0.061 CHF
High0.061 CHF
Low0.052 CHF
Close (prev. day)0.058 CHF
VWAP0.056823 CHF
Volume (pcs)608,390
Trading volume34,570.38
Number of trades49
Last size841

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: ADDEX THERAPEUTICS LIMITEDPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/08/16 17:31:02
Price
0.052 CHF
Difference -10.34% (-0.01)

General attributes

ISINCH0029850754
SymbolADXN
ExchangeSIX Swiss Exchange
CurrencyCHF
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)5 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)0.052 CHF (32,183)
Ask (Ask size)0.0578 CHF (100)
Open0.061 CHF
High0.061 CHF
Low0.052 CHF
Close (prev. day)0.058 CHF
VWAP0.056823 CHF
Volume (pcs)608,390
Trading volume34,570.38
Number of trades49
Last size841

Performance and Risk

6m1Y3Y
Perf (%)-27.78%-41.96%-96.74%
Perf (abs.)-0.02-0.04-1.54
Beta0.651.270.85
Volatility136.93123.34108.69
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)0.057 CHF (222,895)
Ø price 30 days | Ø volume 30 days (pcs.)0.060 CHF (108,792)
Ø price 100 days | Ø volume 100 days (pcs.)0.082 CHF (747,734)
Ø price 250 days | Ø volume 250 days (pcs.)0.070 CHF (561,941)
YTD High | date0.260 CHF (2024/04/09)
YTD Low | date0.045 CHF (2024/01/03)
52 Weeks High | date0.260 CHF (2024/04/09)
52 Weeks Low | date0.036 CHF (2023/11/29)

All listings for ADDEX THERAPEUTICS LIMITED

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Stuttgart2019/06/2815:431.37 EUR0.007
SIX Swiss Exchange2024/08/1617:310.052 CHF0.0349
London Stock Exchange2024/05/0217:550.064 CHF0.011
Frankfurt2019/06/2817:141.355 EUR0.007
Berlin2019/06/2815:581.37 EUR0.005

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=19965&ID_TYPE_IMAGE_LOGO=2

Contact Details

ADDEX THERAPEUTICS LTD.
- -
9, Chemin des Mines, Plan-les-Ouates - 1202 Genf
Telefon: +41-22-884-15-55
Fax: +41-22-884-15-56
E-mail: info@addextherapeutics.com

PDF Downloads

Company report: ADDEX THERAPEUTICS LIMITEDPDF Download

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Members of Management Board

Timothy DyerChairman of Managing Board
Lénaic TeyssédouMember of Executive Committee
Mikhail KalinichevMember of Executive Committee
Roger MillsMember of Executive Committee

Board of directors

Isaac MankeMember of the administrative board
Raymond HillMember of the administrative board
Roger MillsMember of the administrative board
Jake NunnMember of the administrative board
Vincent LawtonChairman of the administrative boar





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer